← Back to patent-cliff list
Pradefovir Mesylate
Tier C — Watch / tradePradefovir Mesylate
Metabasis Therapeutics Inc
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HBV pol
Indications (approved)：Chronic hepatitis B
Regional status
US
-
EU
-
China
Approved
2024-10-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pradefovir Mesylate?
Approved indications include: Chronic hepatitis B.
When does the Pradefovir Mesylate patent expire?
No public expiry year is available for Pradefovir Mesylate yet; this page updates once verified.
How do I get a quote for Pradefovir Mesylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27